secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2023-06-12T23:59:59+00:00
Accession:  0001193125-23-164890
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NTLA-2002 Phase 1 data: 95% mean HAE attack reduction; 9 of 10 patients attack free
--------------------------------------------------------------------------------

- Single 25-75 mg dose of NTLA-2002 (n=10) produced 95% mean reduction in monthly HAE attack rate through median 9-month follow-up.
- All 9 patients achieving >60% plasma kallikrein reduction remain completely attack free since 16-week observation; longest attack-free interval 13.0 months.
- All 6 patients who discontinued long-term HAE prophylaxis after NTLA-2002 have reported no subsequent attacks.
- Safety: no dose-limiting toxicities, no serious adverse events, no Grade 3+ events; most adverse events mild and transient.
- Phase 2 portion of study now dosing; Intellia expects to complete enrollment in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312523164890/0001193125-23-164890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312523164890/d517852d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-164890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer